Results 171 to 180 of about 92,725 (294)

Continuous Renal Replacement Therapy During Liver Transplant: The Anesthesiologist-Nephrologist Collaboration at a Tertiary University Hospital in Italy. [PDF]

Clin Transplant
Laici C, Ricci D, Gibertoni D, Mancini E, Zucchelli A, Siniscalchi A.   +5 more
europepmc   +1 more source

Continuous Renal Replacement Therapy

Acta clinica Croatica, 2000
Akutno zatajenje bubrega (AZB) danas se najčešće javlja u sklopu složenih sindroma poput sepse i/ili višestrukog zatajenja organa. Napredak na području hemodijalize doveo je do usporednog razvoja novih tehnika liječenja koje se temelje na kontinuiranoj nadoknadi bubrežne funkcije.
openaire   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

British Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga, Stefano Agliardi, Riccardo Giossi, Alice Schianchi, Alessandra Romandini, Thomas Virdis, Silvia Nerini Molteni, Maria Luisa De Angelis, Stefania Paccagnini, Cecilia Gechtman, Alice Proto, Marco Fossati, Silvia Oliveri, Giulia Angela Pattarino, Elena Altieri, Agnese Graziosi, Arianna Pani, Romano Danesi, Stefano Martinelli, Costantino De Giacomo, Francesco Scaglione   +20 more
wiley   +1 more source

Impacts of hemoperfusion combined with continuous renal replacement therapy on renal function and immune function in patients with acute renal failure caused by poisoning. [PDF]

Front Med (Lausanne)
Fang H, Huang J, Fan S, Xu Y, Liu J.
europepmc   +1 more source

Supratherapeutic drug concentration triggers: A novel data‐driven approach to assess their value for medication safety surveillance in intensive care

British Journal of Clinical Pharmacology, EarlyView.
Aims Electronic triggers (e‐triggers) are used as screening signals to detect potential adverse drug events (ADEs) and offer an effective system level approach for medication safety surveillance. Their clinical utility is typically evaluated through time‐consuming manual chart review by experts, limiting implementation.
Anne Paulien Langermans, Izak A. R. Yasrebi‐de Kom, Dylan Wayne de Lange, Nicolette Fransisca de Keizer, Joanna E. Klopotowska, on behalf of the RESCUE Study group, C. S. C. Bouman, E. N. van Roon, P. F. Schutte, J. ten Cate, D. van Balen, S. Hendriks, C. Lau, W. J. Vermeijden, A. Beishuizen, J. B. Masselink, P. E. Spronk, H. J. M. van Kan, P. W. de Feiter, E. J. Wils, A. Wieringa, A. J. Valkenburg, W. M. van den Bergh, M. H. Renes, W. Bult, E. de Jonge, M. Hoeksema, E. J. Wesselink, I. M. Purmer, B. E. Bosma, S. H. W. van Bree, H. J. W. Lammers, R. J. Bosman, E. J. F. Franssen, A. Karakus, M. Sigtermans, E. M. Kuck, D. A. Dongelmans, M. J. H. Aries, E. V. Uijtendaal, M. C. Reuland   +40 more
wiley   +1 more source

Discrepancies between declared and real practices of continuous renal replacement therapy for septic acute kidney injury in French intensive care units. [PDF]

Ann Intensive Care
Stephan L, Prevel R, Sazio C, Ilciukas-Miquel H, Auvet A, Bodot S, Chelha R, Coirier V, Fabre X, Garin A, Garraud J, Gisbert-Mora C, Grillet G, Hayon J, Labro G, Lambour A, Lancrey-Javal T, Le Basnier E, Mikulski M, Nicolas J, Olry K, Plouvier F, Seguin T, Tientcheu A, Valette M, Guisset O, Gruson D, Boyer A, Orieux A.   +28 more
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Navigating the Precipice: continuous renal replacement therapy in critically Ill children with oncologic diseases. [PDF]

J Pediatr (Rio J)
Menon S.
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Risk factors and prognostic impact of continuous renal replacement therapy after heart transplantation: a single-center retrospective study. [PDF]

Front Med (Lausanne)
Wu X, Lian PA, Liu JR, Sun XR, Zhou Q, Li L, Wang CA, Zhang JH.   +7 more
europepmc   +1 more source